Premium
Immunomodulatory Therapeutic Proteins in COVID‐19: Current Clinical Development and Clinical Pharmacology Considerations
Author(s) -
Ji Ping,
Chen Jianmeng,
Golding Amit,
Nikolov Nikolay P.,
Saluja Bhawana,
Ren Yunzhao R.,
Sahajwalla Chandrahas G.
Publication year - 2020
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1729
Subject(s) - medicine , covid-19 , clinical trial , pandemic , disease , immunology , coronavirus , intensive care medicine , pharmacology , infectious disease (medical specialty) , virology , outbreak
The coronavirus disease 2019 (COVID‐19) pandemic caused by infection with SARS‐CoV‐2 has led to more than 600 000 deaths worldwide. Patients with severe disease often experience acute respiratory distress characterized by upregulation of multiple cytokines. Immunomodulatory biological therapies are being evaluated in clinical trials for the management of the systemic inflammatory response and pulmonary complications in patients with advanced stages of COVID‐19. In this review, we summarize the clinical pharmacology considerations in the development of immunomodulatory therapeutic proteins for mitigating the heightened inflammatory response identified in COVID‐19.